{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T18:38:03Z","timestamp":1732041483521},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12185-022-03372-2","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T08:11:21Z","timestamp":1652083881000},"page":"622-629","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report"],"prefix":"10.1007","volume":"116","author":[{"given":"Yushi","family":"Chikasawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Bingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kagehiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayano","family":"Mitsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Shinozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Fukutake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ei","family":"Kinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"3372_CR1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","volume":"122","author":"PD James","year":"2013","unstructured":"James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood. 2013;122:636\u201340.","journal-title":"Blood"},{"key":"3372_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1365-2516.2008.01679.x","volume":"14","author":"A Iorio","year":"2008","unstructured":"Iorio A, Oliovecchio E, Morfini M, Mannucci PM. Italian Registry of haemophilia and allied disorders. Objectives, methodology and data analysis. Haemophilia. 2008;14:444\u201353.","journal-title":"Haemophilia"},{"key":"3372_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-1-4613-0331-2_7","volume":"386","author":"PM Mannucci","year":"1995","unstructured":"Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. Adv Exp Med Biol. 1995;386:87\u201392.","journal-title":"Adv Exp Med Biol"},{"key":"3372_CR4","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1055\/s-0037-1607440","volume":"44","author":"M Franchini","year":"2018","unstructured":"Franchini M, Mannucci PM. Alloantibodies in von Willebrand disease. Semin Thromb Hemost. 2018;44:590\u20134.","journal-title":"Semin Thromb Hemost"},{"key":"3372_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjh.13064","volume":"167","author":"MA Laffan","year":"2014","unstructured":"Laffan MA, Lester W, O\u2019Donnell JS, Will A, Tait RC, Goodeve A, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014;167:453\u201365.","journal-title":"Br J Haematol"},{"key":"3372_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1046\/j.1538-7836.2003.00009.x","volume":"1","author":"C Boyer-Neumann","year":"2003","unstructured":"Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D. Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease. J Thromb Haemost. 2003;1:190\u20132.","journal-title":"J Thromb Haemost"},{"key":"3372_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1160\/TH12-03-0136","volume":"108","author":"M Mart\u00edn-Salces","year":"2012","unstructured":"Mart\u00edn-Salces M, Jim\u00e9nez-Yuste V, \u00c1lvarez-Rom\u00e1n MT, Rivas-Pollmar I, de la R\u00faa AR. Management of delivery with FVIII\/VWF concentrates in a pregnant woman with type 3 von Willebrand disease and alloantibodies. Thromb Haemost. 2012;108:796\u20138.","journal-title":"Thromb Haemost"},{"key":"3372_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjh.14805","volume":"182","author":"M Scott","year":"2018","unstructured":"Scott M, Hay CRM, Elkhalifa S, Tower C, Cocker M, Thachil J. Management of pregnancy in type 3 von Willebrand disease with alloantibodies. Br J Haematol. 2018;182:440\u20132.","journal-title":"Br J Haematol"},{"key":"3372_CR9","first-page":"869","volume":"34","author":"CK Kasper","year":"1975","unstructured":"Kasper CK, Aledort LM, et al. Letter: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869\u201372.","journal-title":"Thromb Diath Haemorrh"},{"key":"3372_CR10","first-page":"60","volume":"94","author":"ZM Ruggeri","year":"1979","unstructured":"Ruggeri ZM, Ciavarella N, Mannucci PM, Molinari A, Dammacco F, Lavergne JM, et al. Familial incidence of precipitating antibodies in von Willebrand\u2019s disease: a study of four cases. J Lab Clin Med. 1979;94:60\u201375.","journal-title":"J Lab Clin Med"},{"key":"3372_CR11","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1160\/TH12-02-0089","volume":"108","author":"H Yadegari","year":"2012","unstructured":"Yadegari H, Driesen J, Pavlova A, Biswas A, Hertfelder HJ, Oldenburg J. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients. Thromb Haemost. 2012;108:662\u201371.","journal-title":"Thromb Haemost"},{"key":"3372_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/hae.13075","volume":"22","author":"KM L\u00f6vgren","year":"2016","unstructured":"L\u00f6vgren KM, S\u00f8ndergaard H, Skov S, Wiinberg B. Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models. Haemophilia. 2016;22:657\u201366.","journal-title":"Haemophilia"},{"key":"3372_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ajh.24777","volume":"92","author":"R Kruse-Jarres","year":"2017","unstructured":"Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017;92:695\u2013705.","journal-title":"Am J Hematol"},{"key":"3372_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/1076029607310920","volume":"15","author":"C Sucker","year":"2009","unstructured":"Sucker C, Scharf RE, Zotz RB. Use of recombinant factor VIIa in inherited and acquired von Willebrand disease. Clin Appl Thromb Hemost. 2009;15:27\u201331.","journal-title":"Clin Appl Thromb Hemost"},{"key":"3372_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/MBC.0000000000000865","volume":"31","author":"B Faganel Kotnik","year":"2020","unstructured":"Faganel Kotnik B, Strandberg K, Debeljak M, Kitanovski L, Jazbec J, Benedik-Dolni\u010dar M, et al. von Willebrand factor alloantibodies in type 3 von Willebrand disease. Blood Coagul Fibrinolysis. 2020;31:77\u20139.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"3372_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1600-0609.1987.tb01458.x","volume":"39","author":"PM Mannucci","year":"1987","unstructured":"Mannucci PM, Tamaro G, Narchi G, Candotti G, Federici A, Altieri D, et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol. 1987;39:467\u201370.","journal-title":"Eur J Haematol"},{"key":"3372_CR17","first-page":"348","volume":"125","author":"L Bergamaschini","year":"1995","unstructured":"Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med. 1995;125:348\u201355.","journal-title":"J Lab Clin Med"},{"key":"3372_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1055\/s-0037-1613799","volume":"83","author":"H Tout","year":"2000","unstructured":"Tout H, Obert B, Houllier A, Fressinaud E, Rothschild C, Meyer D, et al. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease. Thromb Haemost. 2000;83:274\u201381.","journal-title":"Thromb Haemost"},{"key":"3372_CR19","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1111\/j.1365-2516.2012.02799.x","volume":"18","author":"H Pergantou","year":"2012","unstructured":"Pergantou H, Xafaki P, Adamtziki E, Koletsi P, Komitopoulou A, Platokouki H. The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor. Haemophilia. 2012;18:e66\u20137.","journal-title":"Haemophilia"},{"key":"3372_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1160\/TH15-10-0780","volume":"116","author":"JN Mahlangu","year":"2016","unstructured":"Mahlangu JN, Ragni M, Gupta N, Rangarajan S, Klamroth R, Oldenburg J, et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016;116:1\u20138.","journal-title":"Thromb Haemost"},{"key":"3372_CR21","first-page":"109","volume":"150","author":"PM Mannucci","year":"1984","unstructured":"Mannucci PM, Mari D. Antibodies to factor VIII-von Willebrand factor in congenital and acquired von Willebrand\u2019s disease. Prog Clin Biol Res. 1984;150:109\u201322.","journal-title":"Prog Clin Biol Res"},{"key":"3372_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s002770050323","volume":"75","author":"J Batlle","year":"1997","unstructured":"Batlle J, Lour\u00e9s E, Vila P, Hern\u00e1ndez MC, M\u00e9ndez JA, Torea J, et al. Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction. Ann Hematol. 1997;75:111\u20135.","journal-title":"Ann Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03372-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03372-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03372-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T18:46:04Z","timestamp":1664304364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03372-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3372"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03372-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"assertion":[{"value":"4 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YC has received honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, Japan Blood Products Organization and CSL-Behring. TH has received research grant from Sanofi Genzyme, and also honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, Japan Blood Products Organization and CSL-Behring. MB has received funding for research as a PI from Chugai Pharmaceuticals, and also honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, and CSL-Behring. KA has received research grants from KM Biologics and also honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, Japan Blood Products Organization and CSL-Behring. KS was an endowed Assistant Professor funded by Baxter\/Baxalta\/Shire and CSL Behring until March 2020. KF has served as a paid consultant for KM Biologics, Chugai Pharmaceuticals and Sekisui Medical, and also honoraria from Bayer, Chugai Pharmaceuticals, Takeda Pharmaceutical, Pfizer, Fujimoto Pharmaceuticals, Sanofi Genzyme, SRL and Sekisui Medical. EK has received research grants from Chugai Pharmaceuticals and CSL-Behring, and also received honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, and CSL-Behring.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}